In this issue:
- Tarlatamab for previously treated SCLC
- Nivolumab + gemcitabine-cisplatin in advanced urothelial carcinoma
- Perioperative durvalumab for resectable NSCLC
- Tailored nivolumab/ ipilimumab approach in metastatic renal-cell carcinoma
- Adjuvant nivolumab in resected stage IIB/C melanoma
- 177Lu-PSMA-617 before maintenance ICI in metastatic prostate cancer
- ctDNA response after pembrolizumab in NSCLC
- Vitamin D supplementation in ICI-treated cancers
- Postchemotherapy adjuvant atezolizumab in resected stage II–IIIA NSCLC
- ICIs for patients with pre-existing organ dysfunction
Please login below to download this issue (PDF)